Matthew Scribner - Inogen Executive Vice President - Operations

INGN Stock  USD 7.97  0.23  2.97%   

President

Mr. Matthew Scribner is no longer Executive Vice President Operations of Inogen, Inc., effective September 17, 2018. He has served as our Executive Vice President, Operations since March 2014. Prior to serving this position, Mr. Scribner served as our Vice President, Operations from 2008 until March 2014, the Director of Manufacturing from 2007 to 2008 and the Director of Supply Chain from 2004 to 2007. From 1998 to 2004, Mr. Scribner worked for Computer Motion, a manufacturer of surgical robots that was acquired by Intuitive Surgical, in various executive capacities, including as a Manufacturing Manager and as a Project Manager. From 1989 to 2013, Mr. Scribner served in the United States Navy as a helicopter pilot, on both active duty and as a reservist. He was mobilized and deployed to Iraq in 2003 to fly in support of Operation Iraqi Freedom. He achieved the rank of Commander and retired from the U.S. Navy in July 2013. Mr. Scribner received a BS degree in Ocean Engineering from the United States Naval Academy since 2014.
Age 49
Tenure 10 years
Professional MarksMBA
Address 859 Ward Drive, Goleta, CA, United States, 93111
Phone805 562 0500
Webhttps://www.inogen.com
Scribner also received an MBA from the University of San Diego.

Inogen Management Efficiency

The company has return on total asset (ROA) of (0.1091) % which means that it has lost $0.1091 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.408) %, meaning that it created substantial loss on money invested by shareholders. Inogen's management efficiency ratios could be used to measure how well Inogen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of March 2024, Return On Capital Employed is likely to grow to -0.24. In addition to that, Return On Assets is likely to grow to -0.3. At this time, Inogen's Deferred Long Term Asset Charges is very stable compared to the past year. As of the 28th of March 2024, Fixed Asset Turnover is likely to grow to 5.60, while Total Assets are likely to drop about 292 M.
The company currently holds 21.92 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Inogen Inc has a current ratio of 5.21, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Inogen until it has trouble settling it off, either with new capital or with free cash flow. So, Inogen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Inogen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Inogen to invest in growth at high rates of return. When we think about Inogen's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Brain EvankoCigna Corp
40
Scott FrommerLaboratory
N/A
Sandra VaartLaboratory
64
Everett NevilleCigna Corp
59
Greg AllenCigna Corp
N/A
Christopher MBACigna Corp
N/A
Jason SadlerCigna Corp
55
Eric PalmerCigna Corp
48
Dean MirabellaCigna Corp
N/A
William KlitgaardLaboratory
61
Matt PerlbergCigna Corp
N/A
AmirAli TalasazGuardant Health
44
Brian CaveneyLaboratory
47
William McDowellCigna Corp
N/A
Jenifer GohEUDA Health Holdings
34
Stephen AndersonLaboratory
N/A
Charles LynchMednax Inc
N/A
Adam PharmDCigna Corp
N/A
Lance BerberianLaboratory
61
Matthew MandersCigna Corp
58
David GuilmetteCigna Corp
51
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California. Inogen operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 1021 people. Inogen Inc (INGN) is traded on NASDAQ Exchange in USA. It is located in 859 Ward Drive, Goleta, CA, United States, 93111 and employs 834 people. Inogen is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Inogen Inc Leadership Team

Elected by the shareholders, the Inogen's board of directors comprises two types of representatives: Inogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Inogen. The board's role is to monitor Inogen's management team and ensure that shareholders' interests are well served. Inogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Inogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Bourque, CFO VP
Scott Beardsley, Director
Bart Sanford, Executive Vice President Operations
Agnes Lee, VP Planning
Philip Corrin, Senior Chain
Jason Somer, General VP
Jennifer Boyer, Executive Officer
Kevin Smith, CEO President
Scott Greer, Independent Director
Benjamin AndersonRay, Independent Director
Scott Wilkinson, Pres and COO
Brenton Taylor, Co-Founder and Executive VP of Engineering
MBA MD, Executive Officer
Kristin Caltrider, CFO VP
Raymond Huggenberger, CEO and Director
Heath Lukatch, Independent Chairman of the Board
Matthew Scribner, Executive Vice President - Operations
Alison Bauerlein, Co-Founder, CFO, Principal Accounting Officer, Executive VP of Fin., Treasurer and Secretary
Nabil Shabshab, Pres CEO
Vijay Paliwal, Senior Enablement
Heather Rider, Director
Michael Sergesketter, Chief President
Loren McFarland, Independent Director
George Parr, Ex Officer
Matthew Pigeon, Investor Officer
Byron Myers, Co-Founder and VP of Marketing
Grgoire Ramade, Executive Officer

Inogen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Inogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Inogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inogen Inc Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the Inogen Inc information on this page should be used as a complementary analysis to other Inogen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for Inogen Stock analysis

When running Inogen's price analysis, check to measure Inogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inogen is operating at the current time. Most of Inogen's value examination focuses on studying past and present price action to predict the probability of Inogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inogen's price. Additionally, you may evaluate how the addition of Inogen to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
CEOs Directory
Screen CEOs from public companies around the world
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Bonds Directory
Find actively traded corporate debentures issued by US companies
Global Correlations
Find global opportunities by holding instruments from different markets
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Is Inogen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inogen. If investors know Inogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.873
Earnings Share
(4.42)
Revenue Per Share
13.62
Quarterly Revenue Growth
(0.14)
Return On Assets
(0.11)
The market value of Inogen Inc is measured differently than its book value, which is the value of Inogen that is recorded on the company's balance sheet. Investors also form their own opinion of Inogen's value that differs from its market value or its book value, called intrinsic value, which is Inogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inogen's market value can be influenced by many factors that don't directly affect Inogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.